NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreakin ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...